Lori Macomber
Director of Finance/CFO bei LEGEND BIOTECH CORPORATION
Vermögen: 426 621 $ am 31.03.2024
Profil
Lori Macomber is currently the Chief Financial Officer at Legend Biotech Corp.
She previously worked as the Business Unit Controller at AMETEK, Inc. from 2018 to 2019, the Assistant VP-Finance Site Leader at Eli Lilly & Co. from 2010 to 2017, and the Controller & Chief Financial Officer-US Region at Cello Health Ltd.
from 2017 to 2018.
Ms. Macomber obtained her undergraduate degree from The Pennsylvania State University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
LEGEND BIOTECH CORP.
0,01% | 31.12.2022 | 15 212 ( 0,01% ) | 426 621 $ | 31.03.2024 |
Aktive Positionen von Lori Macomber
| Unternehmen | Position | Beginn |
|---|---|---|
| LEGEND BIOTECH CORPORATION | Director of Finance/CFO | 09.05.2022 |
Ehemalige bekannte Positionen von Lori Macomber
| Unternehmen | Position | Ende |
|---|---|---|
| AMETEK, INC. | Corporate Officer/Principal | 01.09.2019 |
| CELLO HEALTH PLC | Comptroller/Controller/Auditor | 01.02.2018 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01.04.2017 |
Ausbildung von Lori Macomber
| The Pennsylvania State University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| AMETEK, INC. | Producer Manufacturing |
| ELI LILLY AND COMPANY | Health Technology |
| LEGEND BIOTECH CORPORATION | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Cello Health Ltd.
 Cello Health Ltd. Miscellaneous Commercial ServicesCommercial Services Cello Health Plc provides strategic marketing services. It operates through two segments: Cello Health and Cello signal. The Cello Health segment provides market research, consulting, and communications services principally to its pharmaceutical and healthcare clients and Signal segment provides market research and direct communications services principally to its consumer facing clients. The company was founded by Mark Coleridge Scott and Kevin Barrie Steeds on May 5, 2004 and is headquartered in London, the United Kingdom. | Commercial Services |
